Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kalaris Therapeutics Inc (KLRS)
USD4.57
+0.02 (+0.33%)
US NASDAQ Healthcare Biotechnology
Address
139 Main Street, Suite 500 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Andrew Oxtoby
Website
kalaristx.com
IPO
2020-07-30
CIK 1754068 ISIN US4829291065
Also trades on
NASDAQ Global Market · KLRS (USD)
NASDAQ Global Select · ALVR (USD)
Description
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.
News Sentiment (7d)
Based on only 1 article — low confidence
- Kalaris Appoints Laurie Keating to Board of Directors GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.57
+0.02 (+0.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
89.6K
Beta
0.19
Float Shares
4.02M
Free Float %
21.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.27% | -7.35% | -24.09% | -44.62% | -10.13% | -43.25% | +47.38% | -99.79% | -99.96% | -99.96% | -98.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
4.57
Low
14.00
+206.7%
Consensus
18.67
+309.0%
Median
19.00
+316.2%
High
23.00
+403.8%
DCF (Unlevered)
6.25
+36.9%
DCF (Levered)
6.33
+38.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
14.00
+206.7%
|
| Last Quarter | 2 |
18.50
+305.3%
|
| Last Year | 4 |
14.75
+223.1%
|
| All Time | 4 |
14.75
+223.1%
|
Quality scores
Altman Z-Score
-0.67
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+75.7% ★ Q1'26: +81.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +173.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+204.8% Q1'26: +485.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 4 Rev. Ana. 5 EPS Ana. |
Dec 2028 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 375.0K (-100.0%)
|
—
est: 382.5K (-100.0%)
|
—
|
—
|
—
— – —
|
13.33M
13.33M – 13.33M
|
—
— – —
-100.0% YoY
|
6.67M
6.67M – 6.67M
|
18.69M
18.69M – 18.69M
+180.3% YoY
|
| EBITDA |
-69.71M
|
-169.84M
|
-58.77M
|
-46.14M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-69.78M
|
-170.96M
|
-58.77M
|
-46.15M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-69.78M
est: -226.17M (+69.1%)
|
-171.96M
est: -291.44M (+41.0%)
|
-58.77M
est: -48.38M (-21.5%)
|
-43.44M
est: -43.44M (+0.0%)
|
-29.18M
-34.66M – -23.70M
+32.8% YoY
|
-9.90M
-30.11M – 10.30M
+66.1% YoY
|
-27.92M
-36.31M – -19.52M
-181.8% YoY
|
-27.89M
-27.89M – -27.89M
+0.1% YoY
|
-27.79M
-27.79M – -27.79M
+0.4% YoY
|
| SGA |
21.65M
|
49.08M
|
42.92M
|
15.39M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-59.67
est: -45.16 (-32.1%)
|
-63.00
est: -58.19 (-8.3%)
|
-11.73
est: -9.66 (-21.4%)
|
-2.85
est: -3.38 (+15.7%)
|
-1.93
-2.27 – -1.55
+42.8% YoY
|
-1.41
-1.97 – 0.67
+27.0% YoY
|
-1.93
-2.38 – -1.28
-36.9% YoY
|
-1.83
-1.83 – -1.83
+5.5% YoY
|
-1.82
-1.82 – -1.82
+0.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-13 | Citizens | Market Outperform | Market Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.25M
OE per share TTM
-3.95
Owner's Yield
-23.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
32,958.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
18
Total invested
3.53M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
18
-33 vs prev Q
New positions
7
Closed positions
40
Increased
11
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SAMSARA BIOCAPITAL, LLC | 12.95M +1.5M (+13.1%) | 109.28M +43.1M (+65.2%) | 69.23% +8.019 pp | 11.27% +2.636 pp | USD8.08 +4.5% | 4 qtrs — |
| 2 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 4.0K +4.0K (+100.0%) | 33.76M +33.8M (+100.0%) | 0.02% +0.021 pp | 0.03% +0.029 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 3 | RTW INVESTMENTS, LP | 1.30M +1.3M (+100.0%) | 10.97M +11.0M (+100.0%) | 6.95% +6.951 pp | 0.11% +0.110 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 4 | PARADIGM BIOCAPITAL ADVISORS LP | 700.0K +700.0K (+100.0%) | 5.91M +5.9M (+100.0%) | 3.74% +3.743 pp | 0.15% +0.151 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 5 | SIREN, L.L.C. | 435.8K +117.5K (+36.9%) | 3.68M +1.8M (+99.9%) | 2.33% +0.628 pp | 0.11% +0.038 pp | USD7.96 +6.0% | 4 qtrs — |
| 6 | ALYESKA INVESTMENT GROUP, L.P. | 403.6K +403.6K (+100.0%) | 3.40M +3.4M (+100.0%) | 2.16% +2.158 pp | 0.01% +0.010 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 7 | IKARIAN CAPITAL, LLC | 360.0K +360.0K (+100.0%) | 3.04M +3.0M (+100.0%) | 1.93% +1.925 pp | 0.24% +0.237 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 8 | VANGUARD GROUP INC | 292.8K +89.7K (+44.2%) | 2.47M +1.3M (+110.6%) | 1.57% +0.480 pp | 0.00% +0.000 pp | USD7.32 +15.3% | 4 qtrs — |
| 9 | ADAR1 CAPITAL MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 844.0K +844.0K (+100.0%) | 0.53% +0.535 pp | 0.06% +0.062 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 10 | WOODLINE PARTNERS LP | 100.0K -141.1K (-58.5%) | 844.0K -549.6K (-39.4%) | 0.53% -0.755 pp | 0.00% -0.003 pp | USD5.78 +46.0% | 4 qtrs — |
| 11 | — | 97.5K +97.5K (+100.0%) | 822.8K +822.8K (+100.0%) | 0.52% +0.521 pp | 0.63% +0.634 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 12 | BOOTHBAY FUND MANAGEMENT, LLC | 92.3K +92.3K (+100.0%) | 778.7K +778.7K (+100.0%) | 0.49% +0.493 pp | 0.01% +0.012 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 13 | RAYMOND JAMES FINANCIAL INC | 88.4K +88.4K (+100.0%) | 746.4K +746.4K (+100.0%) | 0.47% +0.473 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 3 qtrs — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 87.8K -25.0K (-22.2%) | 740.6K +88.9K (+13.6%) | 0.47% -0.134 pp | 0.00% +0.000 pp | USD4.03 +109.4% | 4 qtrs — |
| 15 | REDMILE GROUP, LLC | 83.0K +— (+0.0%) | 700.1K +220.7K (+46.0%) | 0.44% +0.000 pp | 0.05% +0.005 pp | USD8.03 +5.1% | 4 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 82.6K +18.1K (+28.0%) | 697.6K +324.5K (+87.0%) | 0.44% +0.097 pp | 0.00% +0.000 pp | USD7.06 +19.5% | 4 qtrs — |
| 17 | 683 CAPITAL MANAGEMENT, LLC | 80.6K +80.6K (+100.0%) | 680.2K +680.2K (+100.0%) | 0.43% +0.431 pp | 0.03% +0.030 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 18 | MARSHALL WACE, LLP | 72.9K +58.8K (+416.3%) | 615.1K +533.5K (+653.9%) | 0.39% +0.314 pp | 0.00% +0.001 pp | USD8.36 +1.0% | 4 qtrs — |
| 19 | PROPEL BIO MANAGEMENT, LLC | 42.1K +42.1K (+100.0%) | 354.9K +354.9K (+100.0%) | 0.22% +0.225 pp | 0.30% +0.303 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 20 | FORTIS CAPITAL ADVISORS, LLC | 40.0K +— (+0.0%) | 337.6K +106.4K (+46.0%) | 0.21% +0.000 pp | 0.05% +0.013 pp | USD5.78 +46.0% | 2 qtrs — |
| 21 | BELPOINTE ASSET MANAGEMENT LLC | 40.0K +— (+0.0%) | 337.6K +106.4K (+46.0%) | 0.21% +0.000 pp | 0.01% +0.003 pp | USD5.78 +46.0% | 2 qtrs — |
| 22 | BLACKROCK, INC. | 38.5K -1.9K (-4.8%) | 324.6K +91.2K (+39.1%) | 0.21% -0.010 pp | 0.00% +0.000 pp | USD6.49 +30.0% | 4 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 34.3K +11.8K (+52.7%) | 289.5K +159.7K (+123.0%) | 0.18% +0.063 pp | 0.00% +0.000 pp | USD6.70 +26.0% | 2 qtrs — |
| 24 | JANE STREET GROUP, LLC | 33.1K +33.1K (+100.0%) | 279.5K +279.5K (+100.0%) | 0.18% +0.177 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 25 | OMERS ADMINISTRATION CORP | 30.0K +30.0K (+100.0%) | 253.2K +253.2K (+100.0%) | 0.16% +0.160 pp | 0.00% +0.002 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 26 | MORGAN STANLEY | 27.9K +3.0K (+12.2%) | 235.9K +91.9K (+63.8%) | 0.15% +0.016 pp | 0.00% +0.000 pp | USD6.10 +38.4% | 4 qtrs — |
| 27 | TWO SIGMA INVESTMENTS, LP | 27.8K +27.8K (+100.0%) | 234.3K +234.3K (+100.0%) | 0.15% +0.148 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 28 | STATE STREET CORP | 25.4K +2.8K (+12.4%) | 214.5K +83.8K (+64.1%) | 0.14% +0.015 pp | 0.00% +0.000 pp | USD7.02 +20.2% | 4 qtrs — |
| 29 | SQUAREPOINT OPS LLC | 25.4K -14.8K (-36.9%) | 214.1K -18.1K (-7.8%) | 0.14% -0.079 pp | 0.00% +0.000 pp | USD3.99 +111.5% | 4 qtrs — |
| 30 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 22.5K +— (+0.0%) | 189.9K +59.9K (+46.0%) | 0.12% +0.000 pp | 0.00% +0.001 pp | USD5.78 +46.0% | 2 qtrs — |
| 31 | SIMPLIFY ASSET MANAGEMENT INC. | 20.1K +20.1K (+100.0%) | 169.4K +169.4K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.003 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 32 | RBF CAPITAL, LLC | 17.4K +— (+0.0%) | 146.8K +46.3K (+46.0%) | 0.09% +0.000 pp | 0.01% +0.002 pp | USD8.03 +5.1% | 4 qtrs — |
| 33 | NORTHERN TRUST CORP | 13.7K +13.7K (+100.0%) | 115.2K +115.2K (+100.0%) | 0.07% +0.073 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 34 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12.9K +12.9K (+100.0%) | 108.5K +108.5K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 35 | WALLEYE CAPITAL LLC | 11.2K +11.2K (+100.0%) | 94.7K +94.7K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 36 | XTX TOPCO LTD | 10.9K +10.9K (+100.0%) | 92.0K +92.0K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.002 pp | USD8.44 +0.0% | 3 qtrs — |
| 37 | KEEL POINT, LLC | 10.2K +10.2K (+100.0%) | 86.3K +86.3K (+100.0%) | 0.05% +0.055 pp | 0.01% +0.005 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 38 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 10.2K +10.2K (+100.0%) | 85.7K +85.7K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 39 | JOHNSON FINANCIAL GROUP, INC. | 10.0K +— (+0.0%) | 84.4K +26.6K (+46.0%) | 0.05% +0.000 pp | 0.00% +0.001 pp | USD5.78 +46.0% | 2 qtrs — |
| 40 | FMR LLC | 7.8K +— (+0.0%) | 65.9K +20.8K (+46.0%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD8.03 +5.1% | 4 qtrs — |
| 41 | BANK OF AMERICA CORP /DE/ | 6.7K +6.5K (+2,989.4%) | 56.6K +55.3K (+4,412.1%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD8.43 +0.1% | 4 qtrs — |
| 42 | BARCLAYS PLC | 6.1K +6.1K (+100.0%) | 51.2K +51.2K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 43 | UBS GROUP AG | 2.7K -2.6K (-48.8%) | 22.7K -7.6K (-25.2%) | 0.01% -0.014 pp | 0.00% +0.000 pp | USD7.54 +11.9% | 4 qtrs — |
| 44 | ROYAL BANK OF CANADA | 113.00 +113.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD8.43 +0.1% | 1 qtrs NEW |
| 45 | FORTITUDE FAMILY OFFICE, LLC | 114.00 +114.0 (+100.0%) | 962.00 +962.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD8.44 +0.0% | 1 qtrs NEW |
| 46 | BNP PARIBAS ARBITRAGE, SNC | 52.00 -89.0 (-63.1%) | 439.00 -376.0 (-46.1%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD7.48 +12.8% | 4 qtrs — |
| 47 | JPMORGAN CHASE & CO | 50.00 +— (+0.0%) | 422.00 +133.0 (+46.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.02 +5.2% | 4 qtrs — |
| 48 | PARALLEL ADVISORS, LLC | 49.00 +— (+0.0%) | 414.00 +131.0 (+46.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.02 +5.2% | 4 qtrs — |
| 49 | SBI SECURITIES CO., LTD. | 5.00 -3.0 (-37.5%) | 42.00 -4.0 (-8.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.40 +251.7% | 3 qtrs — |
| 50 | CITIGROUP INC | 1.00 +— (+0.0%) | 8.00 +2.0 (+33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 +68.8% | 2 qtrs — |
| 51 | FARTHER FINANCE ADVISORS, LLC | — -33.0 (-100.0%) | — -191.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 52 | FEDERATED HERMES, INC. | — -578.0 (-100.0%) | — -3.3K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 53 | MILLENNIUM MANAGEMENT LLC | — -24.9K (-100.0%) | — -144.1K (-100.0%) | 0.00% -0.133 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
| 54 | TANG CAPITAL MANAGEMENT LLC | — -418.2K (-100.0%) | — -2.4M (-100.0%) | 0.00% -2.236 pp | 0.00% -0.093 pp | USD— | 4 qtrs SOLD |
| 55 | STRENGTHENING FAMILIES & COMMUNITIES, LLC | — -268.0 (-100.0%) | — -1.5K (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 115.1K | 0.60% |
| 2 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 14.9K | 0.14% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 372.7K | 0.05% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 578.39 | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.9K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 7.8K | 0.17% |
| 7 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.34M | 0.03% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.9K | 0.22% |
| 9 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 11.8K | 0.17% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.6K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
452.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+452,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Hagen Brett R | Officer | S-Sale | D | Common Stock | 1,915 | 6.72 | 12.9K | 0 | D | ↗ |
| 2026-03-19 | Oxtoby Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 222,000 | 6.81 | 1.51M | 222,000 | D | ↗ |
| 2026-03-19 | Hagen Brett R | Officer | A-Award | A | Stock Option (Right to Buy) | 60,800 | 6.81 | 414.0K | 60,800 | D | ↗ |
| 2026-03-19 | Gall Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 6.81 | 647.0K | 95,000 | D | ↗ |
| 2026-03-19 | Feinsod Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 6.81 | 919.4K | 135,000 | D | ↗ |
| 2025-12-22 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Common Stock | 1,500,000 | 10.00 | 15.00M | 1,500,000 | I | ↗ |
| 2025-12-18 | AKKARAJU SRINIVAS | Director / 10% Owner | P-Purchase | A | Common Stock | 479,847 | 10.42 | 5.00M | 1,979,847 | I | ↗ |
| 2025-11-03 | Gall Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 235,000 | 4.99 | 1.17M | 235,000 | D | ↗ |
| 2025-04-10 | PATTERSON LEONE D | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-10 | PATEL SAMIR CHANDRAKANT | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-10 | Oxtoby Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 287,000 | 7.31 | 2.10M | 287,000 | D | ↗ |
| 2025-04-10 | Jovan-Embiricos Morana | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-10 | Hagen Brett R | Officer | A-Award | A | Stock Option (Right to Buy) | 50,262 | 7.31 | 367.4K | 50,262 | D | ↗ |
| 2025-04-10 | Ferrara Napoleone | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-10 | Feinsod Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 101,000 | 7.31 | 738.3K | 101,000 | D | ↗ |
| 2025-04-10 | AKKARAJU SRINIVAS | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-10 | ADAMIS ANTHONY P | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 7.31 | 131.6K | 18,000 | D | ↗ |
| 2025-04-03 | PATTERSON LEONE D | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-26 | Hagen Brett R | Officer | S-Sale | D | Common Stock | 907 | 8.97 | 8.1K | 1,925 | D | ↗ |
| 2025-03-18 | Samsara BioCapital GP, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 11,448,081 | I | ↗ |
| 2025-03-18 | PATEL SAMIR CHANDRAKANT | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | Oxtoby Andrew | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | Ferrara Napoleone | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | Feinsod Matthew | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | Dybbs Michael | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | AKKARAJU SRINIVAS | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-18 | ADAMIS ANTHONY P | Director | A-Award | A | Stock Option (right to buy) | 12,989 | 0.55 | 7.1K | 12,989 | D | ↗ |
Executive team
Top executives
Shares Outstanding
18.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brett R. Hagen | Chief Accounting Officer and Principal Accounting & Financial Officer | 1M | male |
| Andrew Oxtoby | President, Chief Executive Officer & Director | 882.0K | male |
| Matthew Feinsod | Chief Medical Officer | 665.4K | — |
| Napoleone Ferrara | Independent Director & Co-Founder | 46.7K | — |
| Michael Philip Dybbs | Director & Co-Founder | 39.0K | — |
| Srinivas Akkaraju | Director & Co-Founder | 39.0K | — |
| Kristine Curtiss | Senior Vice President of Clinical | — | female |
| Jill E. Porter | Senior Vice President of CMC | — | — |
| Matthew Gall | Chief Financial Officer & Treasurer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KLRS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
